If you’re confused about the newest PHE data and want to know if the vaccines are effective against Delta (B.1.617.2) the answer is YES, indeed they are. Do you need both doses? YES, indeed you do. By the way, they’re effective against infection AND severe disease. Let’s discuss.
As of June 7th:
•Infections: 68% unvaccinated, 6% fully vaccinated
•Hospital Admissions: 65% unvaccinated, 11% fully vaccinated
•Deaths: 55% unvaccinated, 29% fully vaccinated (remember we need to consider age, health conditions, etc.)
Looking at PHE data, during the period of time that Delta became prevalent, there has been NO increase in PCR-positive participants in the SIREN (NHS healthcare workers) cohort overall AND reinfections remain at very LOW numbers.
Overall, 59% of confirmed Delta cases are in unvaccinated individuals. About 2/3 of A&E visits and overnight admissions were from unvaccinated individuals while only about 6% of A&E visits were that were fully vaccinated individuals. See the difference here? Without the vaccines,
we would expect to see these numbers be a lot worse. So, are the vaccines less effective against Delta compared to some of the other variants? Yes, BUT they are STILL EFFECTIVE. Keep in mind that two doses of Pfizer’s vaccine is 88% effective against symptomatic infection alone.
Two doses are about 95% effective at preventing hospital admission with Delta (B.1.617.2), and one dose, about 70% (this here being in reference to Pfizer and AstraZeneca. We are still waiting on efficacy for two doses of AstraZeneca against symptomatic infection).
So, if you ask me, these vaccines are VERY effective exactly where they need to be, and that’s the message we should all be carrying forward. Cases are increasing, but it’s important to pay attention to hospitalizations and deaths as a metric, especially in populations with
higher vaccination numbers. If you’re interested in looking at the briefing for yourself you can find it here: assets.publishing.service.gov.uk/government/upl…. Please see my other posts as well. The conclusion? The vaccines WORK. Against all variants for that matter. Get yours when you can.
An important point to consider when looking at deaths in the report. These will be WITH COVID but not necessarily due TO COVID due to delays in hospitalizations data on reason for attendance (could be broken leg) and delays in death registration data. H/T: @kallmemeg- thank you!
Of the 33,206 Delta cases (28,917 with vaccination status). 1,785 were fully vaccinated and got infected (6.2% of total cases). Of these cases (1,785) 12 died (0.7%). Therefore the risk of getting infected with Delta and dying is much less than 0.7% for a fully vaccinated person.
Based on case data, VE estimates are as follows (that second dose matters):
•VE vs. infection: ~35% after 1 dose and ~80% after 2 doses
•VE vs. hospitalization/death: ~80% after 1 dose and >95% after 2 doses
H/T: @JamesWard73- Thank you! Be sure to read his entire thread!

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Mac n’ Chise 🧬🦠🧫

Mac n’ Chise 🧬🦠🧫 Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @sailorrooscout

9 Jun
A new CDC study finds Moderna’s and Pfizer’s COVID-19 vaccines reduce the risk of infection by 91% for fully vaccinated individuals. For the few individuals who do get COVID, vaccination makes illness milder, shorter, AND appear to be less likely to spread the virus to others!
Importantly, this study is among the first to show that vaccination benefits individuals who get COVID-19 despite being fully vaccinated (14 or more days after their second dose) or partially vaccinated (14 or more days after first dose to 13 days after second dose).
3,975 participants completed weekly SARS-CoV-2 testing for 17 consecutive weeks (from December 13, 2020 to April 10, 2021) in eight U.S. locations. The findings come from four weeks of additional data collected in CDC’s HEROES-RECOVER study of health care workers, first
Read 12 tweets
7 Jun
Some good news for your morning! A recent study out of India shows:
•Both Covishield (AstraZeneca) and Covaxin prompted good immune response after two doses
•95% of participants (N=515, HCWs) showed seropositivity (higher antibodies) after two doses of either vaccine
•A total of 27 breakthrough infections (4.9%) were recorded among respondents who had received both doses of either of the vaccines. Out of these, 25 were mild and two were moderate cases of breakthrough infections
•NO deaths were recorded as a result of breakthrough infections
•Seropositivity rates and median anti-spike antibody titre was significantly higher in Covishield (AstraZeneca) recipients
•Of the 425 Covishield (AstraZeneca) and 90 Covaxin recipients, 98.1% and 80% respectively, showed seropositivity
Read 8 tweets
4 Jun
I figured it was best to make a comprehensive thread concerning the study out of The Lancet concerning variant B.1.617.2 (Delta) after mRNA vaccination to help clear up some confusion. Most aren’t breaking it down into layman’s terms, so allow me. Let’s discuss.
Firstly, 250 people, one study, one assay. Median age was 42, fairly healthy. We have established the evasiveness of B.1.617.2 is similar to B.1.351. Got it? Okay, good. I’ll make this simple and put it into bullet points. Study can be found here: thelancet.com/journals/lance…
•One dose is not enough, two are needed for high levels of nAbs. Yes, we knew this. It also falls in line with PHE data from last week
•EXTREMELY IMPORTANT TO NOTE: Antibody neutralization is NOT the same as vaccine efficacy, as in a 5.8-fold reduction in antibody
Read 14 tweets
1 Jun
This is fantastic! Real-world data out of Butantan Institute São Paulo, Brazil shows after ~75% of Serrana’s population had been vaccinated with Coronavac:

•95% reduction in deaths
•86% reduction in hospitalizations
•90% reduction in IC
•80% reduction in symptomatic cases
Total vaccinated population: 27,150 (97.7% of adult population vaccinated with first dose; 95% vaccinated with second dose). Keep in mind, this is in the face of variants of concern including P.1. 75% of Serrana’s population had been vaccinated with Coronavac from February-April.
For comparison purposes, Serrana was compared with Jardinópolis, a nearby city. The death curves were similar UNTIL Serrana began vaccinating. After vaccination (first graphic), we can see deaths rose in Jardinópolis (blue) but dropped significantly in Serrana (orange).
Read 8 tweets
29 May
This is so encouraging! A recent study demonstrates detection and longitudinal persistence of SARS-CoV-2 IgG antibodies in the upper respiratory tract following COVID-19 vaccination. What does this mean? Prevention of SARS-CoV-2 infection AND transmission! Let’s discuss!
Researchers enrolled 114 individuals who had received their first dose of Moderna’s vaccine within 3-7 days and collected oral mucosal fluid samples on days 5, 10, 15, and 20 after each vaccine dose. Of those who were naive (no history of previous infection) to SARS-CoV-2
(n = 89), 79 (85.4%) tested positive for SARS-CoV-2 IgG antibodies by time point 2 (10 days +/-2 days after first vaccine dose), and 100% tested positive for SARS-CoV-2 IgG by time point 3 (15 days +/-2 days after first vaccine dose). And that’s with just one dose!
Read 13 tweets
26 May
Immunological memory for the win! Two new studies show immunity to Coronavirus lasts AT LEAST a year, possibly a lifetime, AND improves over time, ESPECIALLY when paired with vaccination!
The first study shows those who had been previously had an infection have cells that retain a memory of the virus persist in their bone marrow and produce antibodies whenever needed, demonstrating a SARS-CoV-2 infection induces a robust antigen-specific,
long-lived humoral immune response in humans. Find that study here: nytimes.com/2021/05/26/hea…. The second study is still being reviewed before publication in Nature but found memory B-cells continue to mature and strengthen for at least 12 months after initial infection!
Read 4 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

:(